
    
      This is an open-label extension study to evaluate long-term safety and tolerability of
      intravenous (IV) anifrolumab in adult participants with moderately-to-severely active SLE.
      Participants must have completed the qualifying Phase 2 study and meet this study criteria in
      order to be eligible.
    
  